OSUR May Launch Several Products Over the Next 12-18 Months
Analysts at ThinkEquity LLC maintain their “buy” rating on OraSure Technologies Inc (NASDAQ: OSUR), while reducing their estimates for the company.
OSUR has signed a mutually beneficial settlement with Inverness Medical Innovations (NYSE: IMA) regarding the lateral flow litigation. According to ThinkEquity LLC, the terms of the agreement are attractive. Moreover, the agreement is in the best interest of shareholders as it removes the overhang of continued legal spending and enhances the potential for opportunities to expand OSUR’s product offerings, ThinkEquity LLC said.
OraSure Technologies has indicated that its EPS for Q4 2009 will be around ($0.10) to ($0.11) due to the cash write-of. ThinkEquity LLC expects OSUR to launch several products over the next 12-18 months.
ThinkEquity LLC has reduced the EPS estimates for 2009 and 2010 from -$0.12 to -$0.14 and from -$0.20 to -$0.21, respectively.
